An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
STAAR Surgical Company (NASDAQ: STAA) will report financial results for the first quarter ended March 29, 2024, on May 7, 2024. The company will host a conference call and webcast to discuss its performance. STAAR is a leading developer, manufacturer, and marketer of Implantable Collamer® Lenses for myopia, astigmatism, and presbyopia, with over 40 years of experience in ophthalmic surgery. The company's lenses provide visual freedom for patients, reducing the need for glasses or contact lenses. STAAR operates manufacturing facilities in the US and Switzerland and markets its products in over 75 countries.
La STAAR Surgical Company (NASDAQ: STAA) annuncerà i risultati finanziari per il primo trimestre conclusosi il 29 marzo 2024, il 7 maggio 2024. La società organizzerà una conferenza telefonica e un webcast per discutere le sue prestazioni. STAAR è un leader nello sviluppo, nella produzione e nel marketing di lenti Collamer® impiantabili per miopia, astigmatismo e presbiopia, con oltre 40 anni di esperienza nella chirurgia oftalmica. Le lenti dell'azienda offrono libertà visiva ai pazienti, riducendo la necessità di occhiali o lenti a contatto. STAAR gestisce impianti di produzione negli Stati Uniti e in Svizzera e commercializza i suoi prodotti in oltre 75 paesi.
STAAR Surgical Company (NASDAQ: STAA) informará sobre los resultados financieros del primer trimestre finalizado el 29 de marzo de 2024, el 7 de mayo de 2024. La compañía realizará una llamada de conferencia y una transmisión web para discutir su desempeño. STAAR es un líder en el desarrollo, fabricación y comercialización de Lentes de Collamer® implantables para miopía, astigmatismo y presbicia, con más de 40 años de experiencia en cirugía oftalmológica. Las lentes de la compañía proporcionan libertad visual para los pacientes, reduciendo la necesidad de gafas o lentes de contacto. STAAR opera instalaciones de fabricación en EE. UU. y Suiza y comercializa sus productos en más de 75 países.
STAAR Surgical 회사 (나스닥: STAA)는 2024년 3월 29일에 끝난 첫 번째 분기의 재무 결과를 2024년 5월 7일에 보고할 예정입니다. 이 회사는 성과에 대해 논의하기 위해 컨퍼런스 콜과 웹캐스트를 개최할 것입니다. STAAR는 근시, 난시 및 노안을 위한 임플란트용 콜라머 렌즈의 개발, 생산 및 마케팅에서 선도적인 개발자, 제조업체이자 마케터로서 안과 수술 분야에서 40년 이상의 경험을 가지고 있습니다. 이 회사의 렌즈들은 환자에게 시각적 자유를 제공하여 안경이나 콘택트렌즈의 필요성을 줄여줍니다. STAAR은 미국과 스위스에 제조 시설을 운영하며, 전 세계 75개국 이상에서 제품을 판매하고 있습니다.
La société STAAR Surgical (NASDAQ : STAA) communiquera ses résultats financiers pour le premier trimestre terminé le 29 mars 2024, le 7 mai 2024. L'entreprise organisera une conférence téléphonique et une webdiffusion pour discuter de ses performances. STAAR est un leader dans le développement, la fabrication et la commercialisation de lentilles Collamer® implantables pour la myopie, l'astigmatisme et la presbytie, avec plus de 40 ans d'expérience dans la chirurgie ophtalmique. Les lentilles de la société offrent une liberté visuelle aux patients, réduisant le besoin de lunettes ou de lentilles de contact. STAAR exploite des installations de production aux États-Unis et en Suisse et commercialise ses produits dans plus de 75 pays.
Die STAAR Surgical Company (NASDAQ: STAA) wird die Finanzergebnisse für das erste Quartal, das am 29. März 2024 endete, am 7. Mai 2024 bekannt geben. Das Unternehmen wird einen Conference Call und ein Webcast abhalten, um seine Leistungen zu diskutieren. STAAR ist ein führender Entwickler, Hersteller und Vermarkter von implantierbaren Collamer®-Linsen für Myopie, Astigmatismus und Presbyopie mit über 40 Jahren Erfahrung in der augenchirurgischen Branche. Die Linsen des Unternehmens bieten den Patienten visuelle Freiheit und verringern die Notwendigkeit für Brillen oder Kontaktlinsen. STAAR betreibt Produktionsstätten in den USA und der Schweiz und vermarktet seine Produkte in über 75 Ländern.
Positive
STAAR Surgical will release financial results for Q1 2024 on May 7, 2024.
The company is a leader in developing Implantable Collamer® Lenses for various eye conditions.
STAAR has a strong presence in over 75 countries with more than 3,000,000 ICLs sold to date.
Negative
Potential risks may include fluctuations in revenue due to market conditions.
Investors should be cautious of any operational challenges discussed during the conference call.
LAKE FOREST, Calif.--(BUSINESS WIRE)--
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia,today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m.Pacific to discuss its financial results and operational progress. To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants. No access code is required. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.
A taped replay of the conference call will be available beginning approximately one hour after the call’s conclusion for seven days. The replay can be accessed by dialing 877-344-7529 for domestic callers and 412-317-0088 for international callers. Please use access code 3030937. An archived webcast will also be available at www.staar.com.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com
Investors & Media
Brian Moore
Vice President, Investor Relations and Corporate Development
(626) 303-7902, Ext. 3023
bmoore@staar.com
Source: STAAR Surgical Company
FAQ
When will STAAR Surgical report its first quarter results?
STAAR Surgical will report its first quarter results on May 7, 2024.
What products does STAAR Surgical specialize in?
STAAR Surgical specializes in the development, manufacturing, and marketing of Implantable Collamer® Lenses for myopia, astigmatism, and presbyopia.
Where is STAAR Surgical headquartered?
STAAR Surgical is headquartered in Lake Forest, California.
How many countries does STAAR Surgical market its products in?
STAAR Surgical markets its products in over 75 countries worldwide.
How can investors access the conference call and webcast?
Investors can access the conference call by dialing 833-816-1164 (domestic) or 412-317-1899 (international), with no access code required. The webcast can be accessed on the investor relations section of the STAAR website.
